Pan-Amyloid Removal & Reversal Of The Underlying Pathology Of Systemic Amyloidosis
Making New Solutions Possible for Patients
AT ATTRALUS, WE SEE A CLEAR FUTURE WHERE MORE IS POSSIBLE FOR PATIENTS WITH SYSTEMIC AMYLOIDOSIS.
Using our proprietary pan-amyloid removal (PAR) technology, we are advancing a pipeline of novel therapeutics that remove toxic, disease-causing amyloid throughout the body with high specificity, and the potential to reverse disease pathology. We are pioneering first-in-class novel pan-amyloid therapies that bind to all types of amyloid, so that our therapies can be used for patients with all types of systemic amyloidosis and at all stages of disease.
Why It Matters
There is a critical unmet need for disease modifying therapies that can remove amyloid across all stages and types of systemic amyloidosis. The existing approved drugs for amyloidosis do not address the toxic amyloid deposits that are present and accumulate in organs and are the cause of disease burden, progressive organ failure and increased mortality in patients.
Our Pioneering Pan-Amyloid Pipeline
Our Pan-Amyloid Removal (PAR) Therapeutics
With the aim to treat all types of patients with systemic amyloidosis and open the door to reversing disease, at Attralus we are advancing our pipeline of product candidates for pan-amyloid removal. We have designed our novel biologics to achieve pan-amyloid removal with superior amyloid binding and immune-mediated phagocytosis.
PAR-Peptide + IgG1 Antibody
AT-02 is a fusion of our PAR-peptide with an IgG1 antibody. The proprietary peptide binds to all types of amyloid and delivers the antibody to the site of disease to stimulate the immune system to remove amyloid.
PAR-SAP + SAP ScFc
AT-03 is a fusion of our PAR-SAP with an IgG1 Fc. The PAR-SAP component mediates binding to all types of amyloid and the ScFc stimulates the immune system to remove amyloid.
PAR-Peptide + Fc
AT-04 is a fusion of our pan amyloid removal (PAR) peptide technology with the Fc component of a human IgG1 antibody. The PAR-peptide mediates binding to all types of amyloid, including Aß, tau, and α-synuclein fibrils. The PAR-peptide can bind to pathological protein fibrils found in neurogenerative diseases. The Fc stimulates the immune system to remove amyloid.
PAR-Peptide + CAR-M
AT-06 is a fusion of our PAR-peptide with human chimeric antigen receptor-macrophages (CAR-M). The use of the CAR in human THP-1 cells enhances phagocytosis of human amyloid extracts.
AT-04 + VNAR BBB Shuttle
AT-07 is a fusion of our pan amyloid removal (PAR) candidate AT-04 with the Brain Shuttle based on single domain variable immunoglobulin new antigen receptor (VNAR) antibody developed by Ossianix. The PAR-peptide found in AT-04 mediates binding to all types of amyloid including Aß, tau, and α-synuclein fibrils. The PAR-peptide can bind to pathological protein fibrils found in neurogenerative diseases. The Fc stimulates the immune system to remove amyloid. The Brain Shuttle was developed by Ossianix to be paired with payloads to improve brain penetration and therapeutic efficacy.
Our Amyloid-Specific Imaging Agents
In support of our therapeutic strategy, we are also developing the world’s first amyloid-specific imaging agent which will improve the clinical journey for patients and dramatically expand the population of those who are diagnosed.
Iodine (I-124) evuzamitide
PAR-Peptide + I-124
AT-01 utilizes our pan-amyloid technology combined with iodine-124 to create an amyloid-specific imaging agent for PET/CT imaging to diagnose and quantify systemic amyloidosis. The peptide radiotracer has been shown in clinical studies to detect many types of amyloid, including AL and ATTR, in major organs such as the heart, kidney, liver and spleen.
PAR-Peptide + 99m Tc
AT-05 utilizes our pan-amyloid technology combined with technetium-99m to create an amyloid-specific imaging agent for SPECT/CT imaging.